Clinical Trials Browser

Phase 2 × OTHER × onvansertib × Clear all

NCT05450965 2025-12-17

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms